Cryo-Cell International, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Description of Business, Basis of Presentation and Significant Accounting Policies (Tables)

Description of Business, Basis of Presentation and Significant Accounting Policies (Tables)

3 Months Ended

Feb. 28, 2023

Schedule of Assets and Liabilities from Contracts With Customers

The following table provides information about assets and liabilities from contracts with customers:


	February 28, 2023		November 30, 2022
Contract assets (sales commissions)	$	633,966	$	615,628
Accounts receivable	$	6,522,456	$	6,043,941
Short-term contract liabilities (deferred revenue)	$	9,253,131	$	9,586,327
Long-term contract liabilities (deferred revenue)	$	37,246,889	$	36,000,059

The Company, in general, requires the customer to pay for processing and storage services at the time of processing. Contract assets include deferred contract acquisition costs, which will be amortized along with the associated revenue. Contract liabilities include payments received in advance of performance under the contract and are realized with the associated revenue recognized under the contract. Accounts receivable consists of amounts due from clients that have enrolled and processed in the umbilical cord blood stem cell processing and storage programs related to renewals of annual plans and amounts due from license affiliates, and sublicensee territories. The Company did not have asset impairment charges related to contract assets in the three months ended February 28, 2023 and 2022.

The following table presents changes in the Company’s contract assets and liabilities during the three months ended February 28, 2023:


	Balance at December 1, 2022		Additions		Deductions			Balance at February 28, 2023
Contract assets (sales commissions)	$	615,628	$	26,436	$	(8,098	)	$	633,966
Accounts receivable	$	6,043,941	$	10,373,235	$	(9,894,720	)	$	6,522,456
Contract liabilities (deferred revenue)	$	45,586,386	$	6,404,429	$	(5,490,795	)	$	46,500,020

The following table presents changes in the Company’s contract assets and liabilities during the three months ended February 28, 2022:


	Balance at December 1, 2021		Additions		Deductions			Balance at February 28, 2022
Contract assets (sales commissions)	$	535,522	$	24,589	$	(6,995	)	$	553,116
Accounts receivable	$	5,253,173	$	8,749,914	$	(8,851,522	)	$	5,151,565
Contract liabilities (deferred revenue)	$	40,632,910	$	3,997,047	$	(3,419,819	)	$	41,210,138

Financial Assets and Liabilities Measured at Fair Value on Recurring Basis

The following table summarizes the financial assets and liabilities measured at fair value on a recurring basis as of February 28, 2023 and November 30, 2022, respectively, segregated among the appropriate levels within the fair value hierarchy:


	Fair Value at		Fair Value Measurements at February 28, 2023 Using
Description	February 28, 2023		Level 1		Level 2		Level 3
Assets:
Marketable securities	$	840,277	$	840,277	$	—	$	—
Total	$	840,277	$	840,277	$	—	$	—
Liabilities:
Contingent consideration	$	998,003	$	—	$	—	$	998,003
Total	$	998,003	$	—	$	—	$	998,003


Contingent Consideration:
Beginning Balance as of November 30, 2022	$	1,162,704
Subtractions – Cord:Use earnout payment		—
Fair value adjustment as of February 28, 2023		(164,701	)
Ending balance as of February 28, 2023	$	998,003


	Fair Value at		Fair Value Measurements at November 30, 2022 Using
Description	November 30, 2022		Level 1		Level 2		Level 3
Assets:
Marketable securities	$	17,620	$	17,620	$	-	$	-
Total	$	17,620	$	17,620	$	-	$	-
Liabilities:
Contingent consideration	$	1,162,704	$	-	$	-	$	1,162,704
Total	$	1,162,704	$	-	$	-	$	1,162,704